High-grade B-cell lymphoma
Revision as of 01:41, 25 June 2023 by Warner-admin (talk | contribs) (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study")
Section editor transclusions Note: High-grade B-cell lymphoma (HGBL) was not considered as a named entity until the 2016 revision of the WHO guidelines, and includes entities such as double-hit lymphoma and triple-hit lymphoma which were previously classified under diffuse large B-cell lymphoma. We will populate this page with relevant regimens over time.
7 regimens on this page
7 variants on this page
|
Relapsed or refractory, subsequent lines of therapy
Lisocabtagene maraleucel monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Abramson et al. 2020 (TRANSCEND NHL-001) | 2016-01-11 to 2019-07-05 | Phase 1 (RT) |
Immunotherapy
- Lisocabtagene maraleucel (Breyanzi) target dose of 100 x 106 CAR T cells IV once on day 0
One course
References
- TRANSCEND NHL-001: Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020 Sep 19;396(10254):839-852. Epub 2020 Sep 1. link to original article contains dosing details in abstract PubMed Clinical Trials Registry
Loncastuximab tesirine monotherapy
Regimen
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Caimi et al. 2021 (LOTIS-2) | 2018-2019 | Phase 2 (RT) |
Antibody-drug conjugate therapy
- Loncastuximab tesirine (Zynlonta) as follows:
- Cycles 1 & 2: 0.15 mg/kg IV over 30 minutes once on day 1
- Cycle 3 onwards: 0.075 mg/kg IV over 30 minutes once on day 1
Supportive therapy
- Dexamethasone (Decadron) 4 mg IV or PO twice per day on days -1 to 2 (3 days total)
21-day cycles for up to 18 cycles (1 year)
References
- LOTIS-2: Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):790-800. Epub 2021 May 11. link to original article contains dosing details in abstract PubMed Clinical Trial Registry